东阳光长江药业(01558.HK)向Apollo授出HEC88473项目许可权

阿斯达克财经
13 Nov 2024

东阳光长江药业(01558.HK) 公布,与Apollo达成授权许可协议,向Apollo授予公司自主研发的HEC88473项目在大中华区以外地区的独家开发和商业化权益,并保留大中华区的开发和商业化权益。

根据协议,公司有望在协议的有效期内收取最高9.38亿美元的款项,包括1,200万美元的首付款和最高9.26亿美元的开发、监管及商业里程碑付款。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-12 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10